Journal
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
Volume 20, Issue 1, Pages 40-46Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/GCO.0b013e3282f40de9
Keywords
basal-like breast cancer; BRCA1; triple negative breast cancer
Categories
Ask authors/readers for more resources
Purpose of review We have made remarkable advances in treatment of breast cancer with combination chemotherapies, hormonal therapies, and modern targeted therapies. Triple negative breast cancers carry a poor prognosis, however, and they are insensitive to most available hormonal or targeted therapeutic agents thus far developed. A better understanding of pathophysiology, natural history, and currently available treatment options is necessary to improve outcomes of patients with triple negative breast cancer. Recent findings Gene expression profiling has allowed us to classify breast cancers into five subtypes based upon distinctive gene expression signatures. This subtyping is prognostic, and the recent literatures suggest that these 'molecular portraits' may be used to predict treatment outcomes in the future. Summary As we prepare for an era of targeted and individualized medicine, limited understanding of triple negative breast cancer biology presents a challenge in developing novel therapies. Identification of more molecular predictive signatures and their prospective validation will enable us to characterize triple negative breast cancers better and design optimal treatment modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available